Clinical Trial Update: Study to Assess the Safety and Immunogenicity of a Single Dose of GlaxoSmithKline's (GSK) Meningococcal MenACWY-CRM Vaccine (Menveo), Administered to Subjects 15 Through 55 Years of Age, Approximately 4-6 Years After Primary ACWY Vaccination [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluated safety and immunogenicity of a single-dose MenACWY-CRM vaccine (Menveo) in individuals aged 15-55, about 4-6 years after prio…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Infections

Drugs mentioned

• Menveo (meningococcal group A, C, W-135 and Y conjugate vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Meningococcal | Phase 3 | Status: COMPLETED | Results posted: 2018-08-03